This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

peginterferon alfa-2a (Pegasys®)

Reference No. 2028

Publication date:

Appraisal information

peginterferon alfa-2a (Pegasys®) 135 micrograms solution for injection
peginterferon alfa-2a (Pegasys®) 180 micrograms solution for injection
peginterferon alfa-2a (Pegasys®) 90 micrograms solution for injection

Company: Roche Products Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 05/03/2018

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, peginterferon alfa-2a (Pegasys®) cannot be endorsed for use within NHS Wales for the treatment of HBeAg-positive chronic hepatitis B in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.
Statement of Advice (SOA)